Current problems in cancer. Case reports最新文献

{"title":"Orbital cellulitis and massive chemosis as first sign of a cilio-choroidal malignant melanoma without extraocular extension: A case report","authors":"Matteo Mario Carlà ,&nbsp;Carmela Grazia Caputo ,&nbsp;Maria Grazia Sammarco ,&nbsp;Federico Giannuzzi ,&nbsp;Chiara Fantozzi ,&nbsp;Gustavo Savino ,&nbsp;Maria Antonietta Blasi ,&nbsp;Monica Maria Pagliara","doi":"10.1016/j.cpccr.2023.100253","DOIUrl":"10.1016/j.cpccr.2023.100253","url":null,"abstract":"<div><h3>Purpose</h3><p>To describe a case of cilio-choroidal melanoma presenting as aseptic orbital cellulitis with massive conjunctival chemosis.</p></div><div><h3>Methods</h3><p>Case report.</p></div><div><h3>Results</h3><p>A 51-year-old man with a left retro-iris pigmented lesion had acute lid edema, conjunctival chemosis, and extensive hyphema. Ultrasound revealed a large, lobulated, wide-base choroidal-starting lesion affecting the ciliary bodies and vitreous chamber. MRI revealed low-intermediate T2-signal and intermediate-high T1-signal, with substantial post-contrastographic enhancement. After one week of systemic corticosteroids, the chemosis reduced significantly, and the patient was referred for enucleation, even without histologic confirmation. Post-surgical histopathology found 90% necrotic tissue, few viable cells, and no scleral or vascular invasion, with genetic analysis showing monosomy of chromosome 3 and 8q gain.</p></div><div><h3>Conclusion</h3><p>Choroidal melanoma, particularly if necrotic, may occasionally present as aseptic orbital cellulitis, even without extraocular spread.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46535821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast metastasis from primary lung cancer and its association with ablative radiotherapy: A case report","authors":"Matthew E. Volpini,&nbsp;Jason R. Pantarotto","doi":"10.1016/j.cpccr.2023.100256","DOIUrl":"10.1016/j.cpccr.2023.100256","url":null,"abstract":"<div><p>This is a case report of a patient with PD-L1 positive metastatic lung adenocarcinoma who underwent palliative and ablative dose radiotherapy directed to metastatic axillary nodal disease and went on to develop localized followed by diffuse breast and cutaneous metastases. This case serves as an example of the potential utility of ablative dose radiotherapy for controlling sites of progression and highlights the risk of ablative radiotherapy for altering lymphatic drainage and promoting retrograde spread of disease. Given the increased incidence of oligometastatic NSCLC, and the increased utilization of ablative dose radiotherapy to treat metastatic sites in this clinical setting, we believe that this article may inform clinical practice. Our results provide additional support for the utility of ablative dose radiotherapy for this patient population and highlight the need for clinicians to employ a patient-specific approach when deciding on treatment, understanding that the use ablative doses of radiotherapy may provide a better chance for radiologic control, but may come at the cost of an increased risk of altered lymphatic drainage and retrograde spread of disease. The case was overseen by a multidisciplinary team consisting of primary care, medical and radiation oncologists as well as palliative care physicians.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43131067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful complete resection and recurrence-free outcome in renal cell carcinoma with vena cava tumor thrombus: Neoadjuvant immune checkpoint inhibitor (ICI)-based combination therapies","authors":"Hirofumi Yoshino,&nbsp;Akihiko Mitsuke,&nbsp;Yoichi Osako,&nbsp;Takashi Sakaguchi,&nbsp;Ryosuke Matsushita,&nbsp;Satoru Inoguchi,&nbsp;Shuichi Tatarano,&nbsp;Yasutoshi Yamada,&nbsp;Hideki Enokida","doi":"10.1016/j.cpccr.2023.100260","DOIUrl":"10.1016/j.cpccr.2023.100260","url":null,"abstract":"<div><p>Treatment of advanced renal cell carcinoma (RCC) typically involves surgery, even in challenging cases (ie, inferior vena cava [IVC] tumor thrombus, stage 3b [T3b] disease). Although tyrosine kinase inhibitor (TKI)-based neoadjuvant therapy shrinks primary tumors for resection, its benefit for T3b disease is limited, and no guidelines recommend it. Immune checkpoint inhibitor (ICI) combinations and TKIs plus ICIs provide new options for unresectable/metastatic RCC, but reports on ICI-based neoadjuvant therapy for T3b disease are scarce, and none describes survival after cytoreductive nephrectomy. In the present study, we have experienced three cases of advanced RCC with level 2 IVC thrombus, in which neoadjuvant therapy with different types of ICI-based combination therapies was utilized. This approach resulted in significant tumor reduction, regression of thrombus, and successful laparoscopic radical nephrectomy. Pathological analysis confirmed complete responses and no residual carcinoma, including metastatic sites. Notably, no recurrence was observed over 1.5 years in all cases. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43258239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review","authors":"Maissoune Hajir ,&nbsp;Ramiz Abu-Hijlih ,&nbsp;Areej Abu Sheikha ,&nbsp;Kholoud Alqasem ,&nbsp;Hikmat Abdel-Razeq","doi":"10.1016/j.cpccr.2023.100243","DOIUrl":"10.1016/j.cpccr.2023.100243","url":null,"abstract":"<div><h3>Introduction</h3><p>The phase-3 MONALEESA-2, -3 and -7 randomized trials showed benefit of CDK4/6 inhibitor, ribociclib, in women with advanced-stage breast cancer. However, ribociclib-induced acute kidney injury (AKI) was not addressed in these studies. In this report, we explore AKI in breast cancer patients receiving ribociclib.</p></div><div><h3>Methods</h3><p>Medical records of all breast cancer patients who received ribociclib at our institution between April 2019 and September 2021 were reviewed. Details of creatinine kinetics in relation to ribociclib administration and other nephrotoxic drugs were obtained. Acute kidney injury grades (AKI-KDIGO classification) were captured.</p></div><div><h3>Results</h3><p>154 females, with advanced-stage breast cancer treated with aromatase inhibitors (AI) or fulvestrant plus ribociclib were reviewed. A total of 29 (18.8%) patients developed AKI; 5 were grade-I, 21 grade-II and 3 were grade-III. Rate of AKI was significantly higher (<em>n</em> = 16, 45.7%) among 35 patients who were on other concomitant nephrotoxic drugs, compared to 11 (9.6%) of 114 other patients, <em>p</em> = 0.001. Median time to develop AKI was 54 (range, 21–168) days, while the median time for creatinine recovery was 5 (range, 4–7) days after holding the drugs. Average creatinine increment for affected patients was 2.28 times the baseline level. Time to AKI was sooner, but not statistically significant, among patients on nephrotoxic drugs and recovery was faster after stopping these drugs.</p></div><div><h3>Conclusion</h3><p>Ribociclib-induced AKI is not uncommon and not adequately addressed. Though reversible in majority of patients, some patients may develop grade-III AKI or require treatment interruption. Nephrotoxic drugs seem to significantly enhance ribociclib-associated renal injury, withholding these drugs and close follow up is strongly recommended. Prospective studies are warranted to validate these conclusions.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46729694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature","authors":"Bowen He ,&nbsp;Junid A. Naveed Ahmad ,&nbsp;Connie J. Chen ,&nbsp;David M. Aboulafia","doi":"10.1016/j.cpccr.2023.100248","DOIUrl":"10.1016/j.cpccr.2023.100248","url":null,"abstract":"<div><p>Leukapheresis is a resource-intensive and high-risk treatment with unclear benefits when used for leukostasis syndrome in hematologic malignancies. In this case report and literature review we discuss the pathophysiology of leukostasis syndrome associated with chronic lymphocytic leukemia (CLL) and the rapidly evolving paradigm of CLL treatment through the lens of a 51-year-old man who was diagnosed with CLL. He presented with clinical manifestations of leukostasis syndrome with an absolute lymphocyte count of 522.6×109/L. We identified 15 additional cases of CLL-associated leukostasis syndrome in our literature review. Pulmonary and neurologic manifestations of leukostasis were most common. In combination with pharmacologic cytoreduction, leukapheresis was used successfully in most cases with few reports of complications. In the context of greater adoption of first line therapies for CLL that are known to induce transient leukocytosis, we explore leukapheresis as an adjunctive therapy that can rapidly reduce the lymphocyte count and in select instances possibly mitigate the effects of Bruton's tyrosine kinase inhibitor-induced hyperleukocytosis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46142091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding missing statement in previously published articles","authors":"","doi":"10.1016/j.cpccr.2023.100218","DOIUrl":"10.1016/j.cpccr.2023.100218","url":null,"abstract":"","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45792235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De novo angiosarcoma of the bladder: A case report","authors":"Daniel Pierce ,&nbsp;Zachary M. Connelly ,&nbsp;Frank Boyd ,&nbsp;Kevin Heinsimer","doi":"10.1016/j.cpccr.2023.100259","DOIUrl":"10.1016/j.cpccr.2023.100259","url":null,"abstract":"<div><p>De novo primary angiosarcoma of the bladder in the absence of radiation has only been reported in 20 cases worldwide. If patients with prior a history of radiation or cancer are included this number climbs to nearly 50 reported cases. Here, we report the 21st case of bladder angiosarcoma with primary origin in the absence of any known carcinogenic exposures. We describe a 62-year-old male with intermittent hematuria who had a 2.5 cm bladder mass on a CT scan. He was initially treated with a TURBT down to the muscularis layer without evidence of invasion, followed by discharge from the hospital. Ultimately, the patient underwent definitive management with a radical cystoprostatectomy and bilateral pelvic lymph node dissection. A comprehensive review of the literature was also conducted. Given the nature of these aggressive tumors, most patients expired within one year of diagnosis, but a multimodal approach suggested a survival benefit in four of seven patients. Overall, this is an aggressive tumor with a benign presentation and should be included in the differential as the number of cases reported have increased over the past 50 years.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46032938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan","authors":"Stefano Testa ,&nbsp;James C. Dickerson ,&nbsp;Melinda Telli","doi":"10.1016/j.cpccr.2023.100258","DOIUrl":"10.1016/j.cpccr.2023.100258","url":null,"abstract":"<div><p>The treatment landscape for metastatic triple negative breast cancer has shifted dramatically in the last few years with the introduction of PARP inhibitors, immunotherapy, and antibody drug conjugates. The two antibody drug conjugates, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), were approved by the FDA based on the ASCENT and Destiny-Breast04 trials, respectively. While the antibody targets (Trop-2 and HER2) and compound structures are notably different, both drugs have topoisomerase I inhibitor payloads. Given the payload similarity, the question of if you use one drug will a patient respond to the other one is raised. Here we report the case of a 54-year-old post-menopausal woman with relapsed triple-negative breast cancer in the skin and lymph nodes with a sustained response to T-DXd after progression on SG. We briefly review key differences in the drugs and considerations in therapy sequence. This case shows that T-DXd following SG can potentially have efficacy in patients with HER2-low metastatic breast cancer, though formal studies are needed to quantify the response rate and if the reverse sequence (T-DXd → SG) also has efficacy.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47393625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegfilgrastim-related thoracic aortitis: A case report and literature review","authors":"Chikako Sekine ,&nbsp;Sasagu Kurozumi ,&nbsp;Hirotoshi Kawashima ,&nbsp;Koichi Hirose ,&nbsp;Jun Horiguchi","doi":"10.1016/j.cpccr.2023.100250","DOIUrl":"10.1016/j.cpccr.2023.100250","url":null,"abstract":"<div><p>Pegfilgrastim can prevent febrile neutropenia during chemotherapy and helps maintain treatment intensity. Aortitis is a rare and serious adverse event associated with pegfilgrastim therapy. The mechanism of pegfilgrastim-related aortitis is unknown. We report a case of pegfilgrastim-related thoracic aortitis during breast cancer chemotherapy in a 69-year-old woman. This case report and literature review draws attention towards this rare adverse event with increasing incidence in recent years.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44469970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer","authors":"Parikshit Padhi ,&nbsp;Naga Praneeth Raja","doi":"10.1016/j.cpccr.2023.100257","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100257","url":null,"abstract":"","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49805688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}